Medtronic Inc. has announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of insulin pumps for people with insulin-requiring type 2 diabetes. The OpT2mise study is the largest randomized controlled trial to compare the efficacy and safety of insulin pump therapy versus multiple daily injections (MDI) for poorly controlled type 2 patients.
The randomized, controlled OpT2mise study was sponsored by Medtronic and conducted with participation from 331 patients, ranging in age from 30 to 75 years. Initial six-month study results comparing MiniMed insulin pump therapy to MDI were published in The Lancet in July 2014. During the six-month continuation phase of the study, the MDI group was switched to MiniMed pump therapy and follow-up of both groups was continued, making a total study period of 12 months.
Study findings showed that MiniMed insulin pumps safely provided significant, sustainable and reproducible improvements in glucose control in comparison to MDI. At 12 months, the group that crossed over to MiniMed insulin pumps after an initial six months of MDI doubled their A1C reduction (a blood measurement used to indicate glucose control) from 0.4% to 0.8% while using 19% less insulin.
Initial results of OpT2mise showed that after six months, people with insulin-requiring type 2 diabetes who used insulin pumps achieved better glucose control than those using MDI. Results after one year include:
Glucose control improved significantly for all patients. Patients receiving MDI for the initial six months of the study were able to achieve an additional A1C reduction of 0.8% (p<0.0001) after switching to insulin pump therapy; both groups achieved an identical 1.2% reduction in A1C at the 12-month mark compared to the baselines. The clinical benefit from pump therapy was reproducible. The MDI group, which switched to insulin pump therapy after six months, experienced a similar reduction in A1C to the results seen in the original insulin pump group. Additionally, at the end of the continuation phase, participants who switched from MDI to insulin pump showed a 19.0% reduction in total daily insulin dose, making it equivalent in both treatment arms.
Glucose control with pump therapy was sustained over 12 months. The original pump group had a further 0.1% reduction in A1C to attain a final 12-month value of 7.8%. There was no difference between groups in weight gain.